⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for chronic lymphocytic leukemia

Every month we try and update this database with for chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsNCT03513562
Chronic Lymphoc...
Ibrutinib Resis...
Ibrutinib
Laboratory Biom...
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
ALICIA (Acalabrutinib in CLL Therapy)NCT04746950
Chronic Lymphoc...
- AstraZeneca
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.NCT02315768
Chronic Lymphoc...
GA101
ibrutinib
65 Years - University of California, San Diego
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Cord Blood Natural Killer (NK) Cells in Leukemia/LymphomaNCT02280525
Leukemia
Lenalidomide
Rituximab
Fludarabine
Cyclophosphamid...
NK Cells
Cytarabine
18 Years - 80 YearsM.D. Anderson Cancer Center
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)NCT04809467
Chronic Lymphoc...
Non Hodgkin Lym...
tafasitamab
parsaclisib
18 Years - Incyte Corporation
Oral Valganciclovir Versus ValacyclovirNCT00562770
Chronic Lymphoc...
Leukemia
Valganciclovir
Valacyclovir
16 Years - M.D. Anderson Cancer Center
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).NCT01021358
Lymphoma
Chronic Lymphoc...
Solid Tumors
ABT-263
Ketoconazole
18 Years - Abbott
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaNCT00759603
Chronic Lymphoc...
Small Lymphocyt...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesNCT03263637
Relapsed or Ref...
Acute Myeloid L...
Acute Lymphocyt...
Chronic Lymphoc...
High Risk Myelo...
Chronic Myelomo...
Richter's Syndr...
B-cell Non-Hodg...
T-cell Non-Hodg...
Small Lymphocyt...
Multiple Myelom...
AZD4573
18 Years - 130 YearsAstraZeneca
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsNCT02440685
Lymphoma, Large...
Lymphoma, Mantl...
Lymphoma, Folli...
Cancer
Neoplasm
Tumor
Lymphoma, Malig...
Lymphoma, B-cel...
Lymphoma, Non-H...
B-Cell Chronic ...
B-Cell Leukemia...
B-Lymphocytic L...
Chronic Lymphoc...
Leukemia, Lymph...
Leukemia, Lymph...
Myelofibrosis
Chronic Idiopat...
Idiopathic Myel...
Lymphoma, T Cel...
Peripheral T-Ce...
T-Cell Lymphoma...
ASN002 Dose Esc...
ASN002 RD
18 Years - Asana BioSciences
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaNCT04964908
Chronic Lymphoc...
18 Years - AstraZeneca
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell TransplantationNCT01455051
Chronic Lymphoc...
Ofatumumab
18 Years - 70 YearsGrupo Espanol de trasplantes hematopoyeticos y terapia celular
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)NCT04716075
Chronic Lymphoc...
Chronic Graft-v...
Mantle Cell Lym...
Adverse Event
Response Rate
Acalabrutinib 2...
18 Years - 80 YearsPolish Lymphoma Research Group
Gazyva Infusion Reaction InvestigationNCT03529227
Chronic Lymphoc...
18 Years - Healthy Future
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantNCT06059391
Acute Lymphobla...
Acute Myeloid L...
Chronic Lymphoc...
Chronic Myeloid...
Hematopoietic a...
Hodgkin Lymphom...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Allogeneic Hema...
Biospecimen Col...
Granulocyte Col...
Hematopoietic C...
Multi-peptide C...
Pheresis
Placebo Adminis...
Stem Cell Mobil...
18 Years - City of Hope Medical Center
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to FludarabineNCT01392079
Chronic Lymphoc...
Alemtuzumab
18 Years - University of Ulm
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)NCT06428019
Chronic Lymphoc...
Venetoclax
Acalabrutinib
Obinutuzumab
18 Years - AbbVie
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine TherapyNCT00108108
Chronic Lymphoc...
HCD122
18 Years - Novartis
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .NCT05959694
Chronic Lymphoc...
Small Lymphocyt...
TQB3909 tablet
18 Years - 75 YearsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00290004
Chronic Lymphoc...
Small Lymphocyt...
Leukemia
Lymphoma
motexafin gadol...
18 Years - Pharmacyclics LLC.
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)NCT01539512
Chronic Lymphoc...
Idelalisib
Rituximab
Placebo to matc...
18 Years - Gilead Sciences
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyNCT02717611
Chronic Lymphoc...
ACP-196 (acalab...
18 Years - Acerta Pharma BV
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT02406742
Leukemia, Lymph...
CC-122
Ibrutinib
Obinutuzumab
18 Years - 79 YearsCelgene
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaNCT00769522
Chronic Lymphoc...
Rituximab
Bendamustine
Cyclophosphamid...
Fludarabine
18 Years - German CLL Study Group
Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)NCT01403246
Chronic Lymphoc...
Lenalidomide; C...
60 Years - Gruppo Italiano Malattie EMatologiche dell'Adulto
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaNCT00275054
Chronic Lymphoc...
Fludarabine
Cyclophosphamid...
Rituximab
18 Years - German CLL Study Group
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic LeukemiaNCT01849939
Chronic Lymphoc...
Lymphocytic Lym...
Fludarabin (pos...
18 Years - 70 YearsUniversity Hospital, Clermont-Ferrand
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaNCT02819583
Acute Lymphocyt...
Chronic Lymphoc...
Follicular Lymp...
Mantle Cell Lym...
B-cell Prolymph...
Diffuse Large C...
PCAR-019 (anti-...
18 Years - PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesNCT04504708
Non-hodgkin Lym...
Chronic Lymphoc...
Small Lymphocyt...
ZX-101A
18 Years - Hangzhou Zenshine Pharmaceuticals Co., Ltd.
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaNCT02029443
Chronic Lymphoc...
Small Lymphocyt...
Richter's Syndr...
Prolymphocytic ...
Acalabrutinib
18 Years - 130 YearsAcerta Pharma BV
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01611090
Chronic Lymphoc...
Small Lymphocyt...
Ibrutinib
Bendamustine hy...
Rituximab
Placebo
18 Years - Janssen Research & Development, LLC
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaNCT03609593
Chronic Lymphoc...
Bendamustine
Venetoclax
Rituximab
18 Years - 99 YearsColumbia University
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerNCT05400122
Colorectal Canc...
Hematologic Mal...
Rectum Cancer
Acute Myeloid L...
Myelodysplastic...
Acute Lymphobla...
Chronic Myeloid...
Chronic Lymphoc...
Hodgkin Lymphom...
Non Hodgkin Lym...
Myeloproliferat...
Plasma Cell Mye...
Vactosertib
Fludarabine Pho...
Cyclophosphamid...
IL-2
Natural Killer ...
18 Years - Case Comprehensive Cancer Center
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)NCT04018248
Diffuse Large B...
Follicular Lymp...
Chronic Lymphoc...
Small Lymphocyt...
B Cell Lymphoma
Marginal Zone L...
Waldenstrom Mac...
Peripheral T Ce...
BR101801 (Phase...
BR101801 (Phase...
18 Years - Boryung Pharmaceutical Co., Ltd
Infusion of Allogeneic, 3rd Party CD19-specific T CellsNCT02274506
Blood And Marro...
Leukemia
Lymphoma
Cyclophosphamid...
Fludarabine
T-Cell Infusion
18 Years - 70 YearsM.D. Anderson Cancer Center
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic LeukemiaNCT00276809
Chronic Lymphoc...
alemtuzumab
filgrastim
carmustine
cyclophosphamid...
cytarabine
dexamethasone
etoposide
fludarabine pho...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - 60 YearsGerman CLL Study Group
Lenalidomide and Obinutuzumab for Previously Untreated CLLNCT02371590
Chronic Lymphoc...
Lenalidomide
Obinutuzumab
18 Years - University of California, San Diego
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine GenerationNCT00428233
Chronic Lymphoc...
Leukemia cell h...
18 Years - Dana-Farber Cancer Institute
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyNCT00990587
Hematologic Mal...
Acute Lymphocyt...
Chronic Lymphoc...
Myelodysplasia
Acute Myeloid L...
Chronic Myeloge...
Hodgkin's Disea...
Ciclopirox Olam...
18 Years - University Health Network, Toronto
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesNCT01767766
Non-Hodgkin's L...
Chronic Lymphoc...
Peripheral T-Ce...
Hodgkin's Lymph...
TGR-1202
18 Years - TG Therapeutics, Inc.
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene ExpressionNCT01030913
Chronic Lymphoc...
18 Years - Northwell Health
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid MalignanciesNCT04796675
Acute Lymphocyt...
Chronic Lymphoc...
Non Hodgkin's L...
Fludarabine + C...
18 Years - Wuhan Union Hospital, China
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00090727
Solid Malignanc...
Non-Hodgkin's L...
AQ4N
18 Years - Novacea
Treg Cells for AGVHD in Non-myeloablative UCB TransplantNCT02118311
Hematologic Mal...
T Regulatory ce...
Fludarabine
Cyclophosphamid...
Total Body Irra...
18 Years - 69 YearsMasonic Cancer Center, University of Minnesota
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaNCT01271283
Chronic Lymphoc...
Stage III Chron...
Stage IV Chroni...
Diagnostic Labo...
Lenalidomide
18 Years - National Cancer Institute (NCI)
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525
Chronic Lymphoc...
Small Lymphocyt...
Ublituximab
Umbralisib
Venetoclax
18 Years - TG Therapeutics, Inc.
Cellular Therapy With Cord Blood CellsNCT00427557
Multiple Myelom...
Leukemia
Lymphoma
Fludarabine
Melphalan
Umbilical Cord ...
Rituximab
Peripheral Bloo...
- 80 YearsM.D. Anderson Cancer Center
Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesNCT01474681
Acute Myelocyti...
Acute Lymphocyt...
Chronic Myeloge...
Myelodysplastic...
Chronic Lymphoc...
Marginal Zone L...
Follicular Lymp...
Large-cell Lymp...
Lymphoblastic L...
Burkitt's Lymph...
High Grade Lymp...
Mantle-cell Lym...
Lymphoplasmacyt...
HSC835
10 Years - 55 YearsNovartis
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaNCT00274989
Chronic Lymphoc...
Bendamustine
Rituximab
18 Years - German CLL Study Group
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationNCT00442130
Chronic Lymphoc...
GM-K562 vaccine
stem cell trans...
18 Years - Dana-Farber Cancer Institute
Selenious Yeast in CLL Patients w/o Indication of ChemotherapyNCT05136378
Chronic Lymphoc...
Chronic Lymphoc...
Chronic Lymphoc...
Chronic Lymphoc...
Low Dose Seleni...
High Dose Selen...
17 Years - 99 YearsShanghai Zhongshan Hospital
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaNCT03447808
Chronic Lymphoc...
Daratumumab
Ibrutinib
Laboratory Biom...
Pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )NCT01569295
Chronic Lymphoc...
Idelalisib
Rituximab
Bendamustine
Placebo to matc...
18 Years - Gilead Sciences
Pneumococcal Vaccine in Untreated CLL PatientsNCT01892618
Chronic Lymphoc...
Prevenar 13
Pneumovax
18 Years - 90 YearsKarolinska University Hospital
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaNCT04505254
Chronic Lymphoc...
Small Lymphocyt...
Acalabrutinib
Obinutuzumab
18 Years - M.D. Anderson Cancer Center
Genomic Analysis of Patients With Chronic Lymphocytic LeukemiaNCT01346020
Chronic Lymphoc...
- Universitaire Ziekenhuizen KU Leuven
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT01243190
Chronic Lymphoc...
Ofatumumab
18 Years - M.D. Anderson Cancer Center
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabNCT00946023
Lymphoma
B-cell Lymphoma
Non Hodgkin Lym...
Chronic Lymphoc...
Fludarabine
Cyclophosphamid...
Total body irra...
Tacrolimus
Mycophenolate M...
Rituximab
Allogeneic Bone...
1 Year - 75 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)NCT00758693
Chronic Lymphoc...
Bendamustine
Rituximab
65 Years - University of Kentucky
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)NCT01419691
Chronic Lymphoc...
Small Lymphocyt...
Leukemia, Proly...
auranofin
18 Years - University of Kansas Medical Center
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood CancerNCT00005785
Hematologic Neo...
HIV Infection
GCSF Mobilized ...
- National Institutes of Health Clinical Center (CC)
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantNCT00571662
Acute Myelogeno...
Acute Lymphocyt...
Chronic Myeloge...
Chronic Lymphoc...
Myelodysplastic...
Multiple Myelom...
Non-Hodgkins Ly...
Hodgkins Diseas...
Peripheral T-ce...
Pentostatin
Total-body irra...
Cyclosporine A ...
Mycophenolate M...
G-CSF
19 Years - 75 YearsUniversity of Nebraska
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic LeukemiaNCT05417165
Chronic Lymphoc...
Small Lymphocyt...
Pneumococcal 20...
Pneumococcal Po...
18 Years - Ohio State University Comprehensive Cancer Center
Safe Accelerated Venetoclax Escalation in CLLNCT04843904
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Obinutuzumab
Rituximab
18 Years - Dana-Farber Cancer Institute
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLNCT01585688
Non-Hodgkin's L...
Chronic Lymphoc...
hLL1-DOX (IMMU-...
18 Years - Gilead Sciences
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT01144260
B-Cell Chronic ...
bafetinib
18 Years - CytRx
SARS-CoV-2 Donor-Recipient Immunity TransferNCT04666025
Accelerated Pha...
Acute Lymphobla...
Acute Myeloid L...
Chronic Lymphoc...
Chronic Phase C...
COVID-19 Infect...
Hematopoietic a...
Hodgkin Lymphom...
Lymphoblastic L...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Biospecimen Col...
Diagnostic Labo...
Electronic Heal...
Questionnaire A...
18 Years - City of Hope Medical Center
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeNCT03310190
Chronic Lymphoc...
18 Years - AbbVie
Safe Accelerated Venetoclax Escalation in CLLNCT04843904
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Obinutuzumab
Rituximab
18 Years - Dana-Farber Cancer Institute
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AMLNCT02238522
Lymphoprolifera...
Acute Myeloid L...
ZEN003365
18 Years - Zenith Epigenetics
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT04852822
Chronic Lymphoc...
Small Lymphocyt...
Biospecimen Col...
Electronic Heal...
18 Years - University of Washington
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasNCT04305444
Relapsed Chroni...
Refractory Chro...
Diffuse Large B...
Follicular Lymp...
Richter's Trans...
DTRM-555
18 Years - Zhejiang DTRM Biopharma
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabNCT00946023
Lymphoma
B-cell Lymphoma
Non Hodgkin Lym...
Chronic Lymphoc...
Fludarabine
Cyclophosphamid...
Total body irra...
Tacrolimus
Mycophenolate M...
Rituximab
Allogeneic Bone...
1 Year - 75 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study Of The Selective PKC-β Inhibitor MS- 553NCT03492125
Chronic Lymphoc...
Small Lymphocyt...
Aggressive Lymp...
MS-553
MS-553
acalabrutinib
venetoclax
Rituximab
obinutuzumab
18 Years - MingSight Pharmaceuticals, Inc
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyNCT02717611
Chronic Lymphoc...
ACP-196 (acalab...
18 Years - Acerta Pharma BV
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)NCT03986034
Chronic Lymphoc...
During Venetocl...
18 Years - National Institutes of Health Clinical Center (CC)
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSNCT00025662
Graft vs Host D...
Myelodysplastic...
Leukemia
Leukemia, Myelo...
Leukemia, Myelo...
Leukemia, Lymph...
Lymphoma
Lymphoma, Mantl...
Lymphoma, Non-H...
Hodgkin Disease
RFT5-SMPT-dgA
Isolex system
18 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanNCT06362044
Chronic Lymphoc...
18 Years - AbbVie
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: